Higher dose of Gleevec leads to increased remission in CML patients

December 08, 2003

SAN DIEGO -- Twice the standard daily dose of Gleevec® results in a significantly higher response rate in treatment of chronic myeloid leukemia (CML), according to researchers at The University of Texas M. D. Anderson Cancer Center.

The study, presented at the annual meeting of the American Society of Hematology (ASH), suggests that patients should routinely receive the higher dose regimen if additional studies continue to show such a dramatic benefit for patients.

"This is a relatively small study, but there is no question that patients who used higher doses of Gleevec clearly showed improvement compared with patients who used a standard dose," says Jorge Cortes, M.D., deputy chair in the Department of Leukemia. "We feel so comfortable with what we are finding that patients being treated at M. D. Anderson already are being given the higher dose therapy."

The study is the first to look at use of high-dose Gleevec in patients with newly diagnosed, early stage CML. Initial dose-escalating studies conducted with CML patients who had failed traditional interferon treatment suggested that patients treated with higher doses of the drug did well, even though a 400-milligram dose was "arbitrarily" selected as the standard, Cortes says.

The researchers compared results of two ongoing consecutive trials being conducted at M. D. Anderson, one using standard dose Gleevec, and the other testing the higher dose in newly diagnosed patients. They found that 18 months after treatment, 28 percent of 114 patients treated with 800 milligrams of Gleevec a day (using two 400 mg pills) had no molecular evidence of disease, compared with 7 percent of 50 patients who used the 400 mg daily dose.

The benefit increased over time. After 24 months, 48 percent of patients using two daily pills had no evidence of disease, compared to 17 percent of patients treated with one pill a day. Now 30 months into the studies, data are still being gathered.

In the group receiving the standard dose, four patients have progressed to advanced disease, but no patients using the higher dose have progressed, Cortes says.

Cortes notes that while some patients on higher doses had lower blood cell counts initially, there is no significant difference in drug tolerance between the two groups. "Overall, higher doses of the drug are very well tolerated," he says.
-end-
Contact: Julie A. Penne, 713-792-0655; jpenne@mdanderson.org
Laura Sussman, 713-792-0655; lsussman@mdanderson.org

University of Texas M. D. Anderson Cancer Center

Related Leukemia Articles from Brightsurf:

New therapeutic approach against leukemia
Using an RNA molecule complex, researchers can prevent retention of cancer stem cell in their tumor supporting niche

Nanoparticle for overcoming leukemia treatment resistance
One of the largest problems with cancer treatment is the development of resistance to anticancer therapies.

Key gene in leukemia discovered
Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

Vitamin B6, leukemia's deadly addiction
Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6.

Artificial intelligence tracks down leukemia
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability.

Milestone reached in new leukemia drug
Using a chemical compound called YKL-05-099, a team of cancer researchers from CSHL and the Dana Farber Institute was able to target the Salt-Inducible Kinase 3 (SIK3) pathway and extend survival in mice with MLL leukemia.

The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.

Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.

Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.

An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.

Read More: Leukemia News and Leukemia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.